Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.739
AS - Asia 5.621
EU - Europa 5.524
SA - Sud America 958
AF - Africa 86
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 5
Totale 25.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.355
SG - Singapore 2.046
CN - Cina 1.366
HK - Hong Kong 1.137
RU - Federazione Russa 1.045
IT - Italia 854
BR - Brasile 789
SE - Svezia 774
IE - Irlanda 728
DE - Germania 633
VN - Vietnam 502
UA - Ucraina 441
GB - Regno Unito 289
CA - Canada 270
FI - Finlandia 173
AT - Austria 159
IN - India 110
FR - Francia 96
TR - Turchia 96
DK - Danimarca 82
AR - Argentina 73
ID - Indonesia 69
MX - Messico 63
RO - Romania 46
JP - Giappone 45
ZA - Sudafrica 45
BD - Bangladesh 42
BE - Belgio 40
IQ - Iraq 38
NL - Olanda 37
PL - Polonia 33
KR - Corea 30
ES - Italia 25
EC - Ecuador 21
CO - Colombia 20
PK - Pakistan 17
CZ - Repubblica Ceca 15
PY - Paraguay 15
CL - Cile 14
IR - Iran 14
SA - Arabia Saudita 14
AE - Emirati Arabi Uniti 12
UZ - Uzbekistan 11
LT - Lituania 10
NP - Nepal 10
VE - Venezuela 10
EU - Europa 9
PA - Panama 9
CH - Svizzera 8
CR - Costa Rica 8
EG - Egitto 8
HN - Honduras 8
PE - Perù 8
DO - Repubblica Dominicana 7
IL - Israele 7
KE - Kenya 7
MA - Marocco 7
AZ - Azerbaigian 6
JO - Giordania 6
PT - Portogallo 6
TN - Tunisia 6
JM - Giamaica 5
OM - Oman 5
UY - Uruguay 5
AL - Albania 4
AU - Australia 4
BG - Bulgaria 4
BH - Bahrain 4
BZ - Belize 4
MY - Malesia 4
TH - Thailandia 4
TW - Taiwan 4
BO - Bolivia 3
GR - Grecia 3
KZ - Kazakistan 3
LB - Libano 3
NG - Nigeria 3
PH - Filippine 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
BY - Bielorussia 2
EE - Estonia 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
ML - Mali 2
MN - Mongolia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
BS - Bahamas 1
CG - Congo 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
Totale 25.928
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Singapore 1.209
Hong Kong 1.134
Ashburn 1.029
Houston 1.022
Chandler 745
Dublin 713
Jacksonville 566
Wilmington 546
Seattle 475
Cambridge 435
Frankfurt am Main 404
New York 371
Dearborn 319
Princeton 280
Milan 256
Beijing 212
Dallas 199
Santa Clara 195
Los Angeles 192
Ho Chi Minh City 150
Nanjing 150
Altamura 133
Lawrence 133
Vienna 122
Moscow 118
Shanghai 117
Lachine 110
Hanoi 108
The Dalles 98
Buffalo 94
Chicago 86
Hefei 85
São Paulo 84
Dong Ket 83
San Diego 74
Ottawa 56
Boardman 52
Andover 51
Fremont 51
Jakarta 51
Munich 47
Nanchang 47
Helsinki 44
Galati 43
London 43
Hebei 41
Brussels 40
Shenyang 40
Toronto 38
Nuremberg 34
Salt Lake City 34
Rio de Janeiro 32
Tokyo 32
Guangzhou 31
Hangzhou 29
Norwalk 29
Seoul 27
Denver 26
Falls Church 25
Montreal 25
Tianjin 24
Changsha 23
Columbus 23
Florence 23
Kent 23
Rome 23
Johannesburg 19
Phoenix 19
Cuauhtémoc 18
Pune 18
Atlanta 17
Edmonton 17
Warsaw 17
Brasília 16
Zhengzhou 16
Jiaxing 15
Kunming 15
Stockholm 15
Amsterdam 14
Boston 14
Brooklyn 14
Council Bluffs 14
Elk Grove Village 14
Mountain View 14
Washington 14
Turku 13
Buenos Aires 12
Baghdad 11
Belo Horizonte 11
Detroit 11
Durban 11
Jinan 11
Miami 11
Quận Bình Thạnh 11
Can Tho 10
Dhaka 10
Kiev 10
Totale 17.573
Salva come PNG Salva come JPEG
Nome #
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 381
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 370
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 303
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 289
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 284
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 279
HIV testing: A must for patients with inflammatory bowel disease 277
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 275
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 266
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 265
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 264
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 261
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 260
Brachial and central blood pressure in HIV-infected subjects 256
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 256
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 254
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 244
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 242
Strategies to limit immune-activation in HIV patients 238
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 237
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 236
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 232
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 232
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 230
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 229
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 224
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 224
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 223
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 222
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 219
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 217
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 215
Unmasking tuberculosis in the era of antiretroviral treatment 212
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 211
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 211
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 210
Focal bone lesions in hiv-positive patient treated with tenofovir 209
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 209
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 209
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 208
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 204
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 203
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 202
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 201
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 201
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 199
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 198
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 196
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 196
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 193
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 190
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 190
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 189
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 189
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 188
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 188
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 188
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 186
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 184
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 183
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 182
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 181
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 181
Effects of antiretroviral therapy on endothelial function in HIV patients. 179
Arterial structure and function in AIDS patients: the impact of renal damage. 178
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 177
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 174
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 172
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 170
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 168
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 168
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 168
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 167
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 167
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 166
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 166
Antimicrobial therapy duration: A major matter in the management of severe infections 165
Re: The challenge of Clostridium difficile infection: Overview of clinical manifestations, diagnostic tools and therapeutic options 165
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 165
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 164
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 163
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 163
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 162
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 160
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 160
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 160
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 159
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 159
Beyond the gut bacterial microbiota: The gut virome 159
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 158
Structural and functional alterations of large arteries in HIV patients and their relationships with metabolic syndrome. 158
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 157
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 157
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 157
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 156
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort) 153
Impact of HAART with protease inhibitors treatment on carotid wall structure in HIV patients. 153
To the editor 152
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 152
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme 150
Totale 20.322
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.045
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.045
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.093 0 0 0 0 0 119 184 151 162 212 89 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20254.704 285 525 358 211 390 156 241 170 571 748 366 683
2025/20265.084 1.129 635 856 1.036 1.270 158 0 0 0 0 0 0
Totale 26.894